No black box warning on record for Pazopanib

As of the latest FDA labeling reviewed, Pazopanib (PAZOPANIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Pazopanib medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatic Toxicity: Severe and fatal hepatotoxicity has occurred. Monitor liver tests at baseline, regularly during treatment and as clinically indicated. Withhold pazopanib tablets and resume at reduced dose with continued weekly monitoring for 8 weeks, or permanently discontinue with weekly monitoring until resolution based on severity of hepatotoxicity. ( 2.2 , 5.1 ) QT

No black box warning on record for Pazopanib

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatic Toxicity: Severe and fatal hepatotoxicity has occurred. Monitor liver tests at baseline, regularly during treatment and as clinically indicated. Withhold pazopanib tablets and resume at reduced dose with continued weekly monitoring for 8 weeks, or permanently discontinue with weekly monitoring until resolution based on severity of hepatotoxicity. ( 2.2 , 5.1 ) QT

Pazopanib Black Box Warning

No black box warning on record for Pazopanib

Other warnings & precautions

Pazopanib Black Box Warning

No black box warning on record for Pazopanib

Other warnings & precautions